Editas Medicine reported Q4 2025 financial results with a net loss of $5.6 million ($0.06 per share), down from $45.4 million in Q4 2024. The company's lead candidate EDIT-401 demonstrated >90% mean LDL-C reduction in preclinical studies and remains on track for IND/CTA submission by mid-2026, with first-in-human trials in HeFH patients expected to begin later in 2026. The company maintains a strong cash position with runway into Q3 2027.
Editas Medicine, Inc. Common Stock (EDIT)
Common Stock · Currency in USD · XNAS
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Company Info
SIC2836
Composite FIGIBBG005MX5GZ2
CIK0001650664
IPOFeb 3, 2016
Sectorbiological products, (no diagnostic substances)
Highlights
Market Cap$261.32M
EPS-$1.12
P/E Ratio-2.60
Revenue$22.24M
Gross Profit$30.17M
Net Income-$100.47M
Employees87
WSO97,871,999
Phone617-401-9000
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Editas Medicine, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Editas Medicine, Inc. Common Stock (EDIT) has returned 29.61% so far this year and 164.36% over the past 12 months. Looking at the last ten years, EDIT has achieved an annualized return of -23.18%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
EDIT
1M22.76%
6M-32.91%
YTD29.61%
1Y164.36%
5Y-42.00%
10Y-23.18%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Editas Medicine, Inc. Common Stock (EDIT) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.40% | 10.55% | 18.75% | 5.95% | ||||||||
| 2025 | 3.15% | 52.38% | -41.12% | 43.48% | 3.61% | 25.00% | 16.20% | 3.63% | 37.70% | -10.98% | -22.51% | -13.50% |
| 2024 | -29.70% | 42.29% | -26.39% | -29.69% | -0.19% | -11.55% | 16.09% | -30.87% | -8.58% | -15.70% | -23.29% | -43.56% |
| 2023 | 8.80% | -12.23% | -19.27% | 13.18% | 13.61% | -10.25% | 6.30% | 2.41% | -13.14% | -14.14% | 57.40% | -4.52% |
| 2022 | -28.77% | -10.97% | -0.11% | -31.29% | -14.04% | 2.42% | 34.60% | -6.79% | -15.72% | 0.48% | -18.46% | -15.92% |
| 2021 | -13.96% | -29.90% | -5.02% | -14.09% | -10.19% | 66.34% | -26.78% | 50.63% | -35.56% | -10.57% | -11.20% | -19.18% |
| 2020 | -11.49% | -16.90% | -11.47% | 17.72% | 19.36% | 6.14% | -1.08% | 17.79% | -19.97% | 9.99% | -2.58% | 128.67% |
| 2019 | -1.36% | -5.32% | 16.32% | 0.08% | -17.80% | 20.57% | -0.63% | -1.66% | -8.34% | -8.68% | 43.51% | -4.48% |
| 2018 | 18.23% | 1.38% | -8.75% | -4.59% | 21.84% | -7.54% | -16.23% | 10.65% | -4.10% | -20.79% | 22.24% | -29.39% |
| 2017 | 5.64% | 42.05% | -10.72% | -16.15% | -27.92% | 20.72% | 0.83% | 23.16% | 13.68% | 1.68% | 15.62% | 6.44% |
| 2016 | -5.57% | 12.16% | -34.25% | 5.19% | -34.68% | -19.76% | 4.74% | 0.49% | 12.63% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Editas Medicine, Inc. Common Stock (EDIT) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of EDIT compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Editas Medicine, Inc. Common Stock volatility is 6.68%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M | 572.60M | 508.89M | 420.39M | 373.26M | 229.18M |
| Equity Attributable To Parent (USD) | 27.29M | 134.27M | 349.10M | 360.68M | 553.64M | 393.59M | 262.44M | 236.16M | 208.08M | 134.61M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 27.29M | 134.27M | 349.10M | 360.68M | 553.64M | 393.59M | 262.44M | 236.16M | 208.08M | 134.61M |
| Other Non-current Liabilities (USD) | - | 72.66M | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | - | 57.43M | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 113.00M | 130.09M | 86.84M | 93.53M | 76.96M | 120.81M | 186.49M | 148.32M | 128.47M | 61.49M |
| Other Current Liabilities (USD) | 38.42M | 60.22M | 43.67M | 40.46M | 31.68M | 46.48M | 49.15M | 25.37M | 28.98M | 25.96M |
| Wages (USD) | 5.22M | 11.52M | 11.28M | 10.14M | 10.16M | 5.32M | 4.97M | 5.20M | 3.71M | 2.48M |
| Accounts Payable (USD) | 2.61M | 5.49M | 8.27M | 9.51M | 5.05M | 6.41M | 5.84M | 5.33M | 4.02M | 4.64M |
| Current Liabilities (USD) | 46.25M | 77.23M | 63.22M | 60.11M | 46.88M | 58.21M | 59.96M | 35.90M | 36.71M | 33.08M |
| Liabilities (USD) | 159.25M | 207.32M | 150.06M | 153.64M | 123.84M | 179.02M | 246.45M | 184.22M | 165.18M | 94.58M |
| Other Non-current Assets (USD) | 19.10M | 37.78M | 146.29M | 142.00M | 153.06M | 139.50M | 34.15M | 5.38M | 1.62M | 1.62M |
| Fixed Assets (USD) | 3.54M | 14.50M | 12.03M | 15.57M | 17.12M | 14.02M | 10.89M | 40.23M | 39.44M | 40.38M |
| Noncurrent Assets (USD) | 22.64M | 52.27M | 158.32M | 157.57M | 170.17M | 153.52M | 45.04M | 45.61M | 41.06M | 42.00M |
| Other Current Assets (USD) | 148.72M | 273.05M | 330.64M | 351.61M | 507.04M | 413.04M | 463.43M | 371.83M | 329.66M | 185.43M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | 2.92M | 1.86M | 1.66M |
| Accounts Receivable (USD) | 15.18M | 16.27M | 10.19M | 5.15M | 267.00K | 6.05M | 418.00K | 30.00K | 679.00K | 88.00K |
| Current Assets (USD) | 163.90M | 289.32M | 340.83M | 356.75M | 507.31M | 419.09M | 463.84M | 374.78M | 332.20M | 187.18M |
| Assets (USD) | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M | 572.60M | 508.89M | 420.39M | 373.26M | 229.18M |
News and Insights
The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.
Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034neutral
The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.
Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.
The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.
2 Beaten-Down Stocks to Avoidnegative
Two biotech companies, Editas Medicine and Sarepta Therapeutics, are experiencing severe challenges that make them unattractive investment options. Editas Medicine lacks marketable products and has a history of abandoned projects, while Sarepta Therapeutics is dealing with patient deaths related to its gene therapy treatment Elevidys.
Editas Medicine is a promising clinical-stage biotech company at the forefront of the gene-editing revolution with its unique in vivo CRISPR approach. However, the company faces significant technical challenges, a long road to commercialization, and weak fundamentals, making it a speculative investment.
Editas Medicine reported new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells with a single dose of its proprietary targeted lipid nanoparticle in non-human primates, supporting the development of a novel in vivo approach to treating sickle cell disease and beta thalassemia.
The growing prevalence of genetic disorders is driving the demand for gene therapy and genome editing solutions. Advancements in technologies like CRISPR-Cas9, TALENs, and base editing have enhanced precision, efficiency, and affordability, making these innovations more accessible to researchers and healthcare professionals.
The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.